Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
AIDS
Interventions
BIOLOGICAL

Ad35-GRIN

intramuscular administration of Ad35-GRIN 5 x 10\^10 vp or saline placebo

BIOLOGICAL

MVA.HIVconsv

IM administration of MVA.HIVconsv 2 x 10\^8 pfu or saline placebo

BIOLOGICAL

pSG2.HIVconsv DNA

IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo

BIOLOGICAL

Electroporated pSG2.HIVconsv

IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo

Trial Locations (1)

Unknown

KAVI-Kangemi clinic, Nairobi

Sponsors
All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

collaborator

International AIDS Vaccine Initiative

NETWORK

collaborator

Karolinska Institutet

OTHER

collaborator

University of Nairobi

OTHER

collaborator

Ichor Medical Systems Incorporated

INDUSTRY

lead

University of Oxford

OTHER

NCT02099994 - Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults | Biotech Hunter | Biotech Hunter